The science behind Berberine.

The most extensively studied area. Four large meta-analyses covering 3,000+ patients consistently show berberine lowers HbA1c by ~0.6–0.7% and fasting glucose by ~0.8 mmol/L — effect sizes comparable to metformin in head-to-head trials.

Berberine reduces hepatic cholesterol production through a mechanism distinct from statins — stabilizing LDL-receptor mRNA and inhibiting PCSK9. Effect sizes are clinically meaningful across multiple meta-analyses.

When all the individual outcomes are pooled together, berberine improves nearly every component of metabolic syndrome simultaneously — a profile no single conventional therapy matches.

Across multiple RCTs in women with polycystic ovary syndrome, berberine improves insulin resistance, androgen profile, LH/FSH ratio, and reproductive outcomes — often outperforming metformin.

Berberine suppresses NF-κB signaling, with measurable reductions in CRP, TNF-α, and IL-6 across large pooled clinical datasets.

Berberine's master mechanism — AMPK activation via mitochondrial complex I and a lysosomal pathway — plus the absorption science behind newer forms like dihydroberberine and phytosome complexes.